<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03621618</url>
  </required_header>
  <id_info>
    <org_study_id>Eadyn project 2</org_study_id>
    <nct_id>NCT03621618</nct_id>
  </id_info>
  <brief_title>Clinical Assessment of Arterial Dynamic Elastance in ICU Patients, Dependent on Inotropic or Vasopressor Drugs.</brief_title>
  <official_title>Clinical Assessment of Arterial Dynamic Elastance in ICU Patients, Dependent on Inotropic or Vasopressor Drugs.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of the study is to determine Eadyn ( = PPV/SVV) as a functional measure of
      arterial load, in conjunction with other actual afterload indices, systemic vascular
      resistance and arterial elastance. A secondary aim is the assessment of the influences of
      vasopressors and inotropic drugs on Eadyn, as a parameter of ventriculo-arterial coupling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of the cardiovascular status and haemodynamics comprise directly or indirectly
      cardiac output, which is determined by left ventricular preload, contractility, afterload and
      heart rate. Various haemodynamic monitors have been introduced in anaesthesia and ICU
      practice, providing cardiac output either non-invasively or invasively. The combined use of
      arterial pressure monitoring with these devices provides insight not only in cardiac output
      but offers bedside assessment of most determinants of cardiovascular function. Both pulse
      pressure variation (PPV) and stroke volume variation (SVV) have been described as dynamic
      descriptors of fluid responsiveness, a measure allowing optimization of preloading conditions
      if haemodynamics show signals of insufficient perfusion.

      Arterial load can be assessed based on a two-element Windkessel model with a static and
      dynamic component. The static part consists of a resistive element (systemic vascular
      resistance: SVR = (MAP/C0)*80, with MAP, mean arterial pressure; CO, cardiac output) and a
      pulsatile component (net arterial compliance C = SV/arterial pulse pressure with SV, stroke
      volume). Arterial elastance is considered being an integrative variable, associating both
      steady elements and heart rate (Ea = .9*SAP/SV with EA, arterial elastance; SAP, systolic
      arterial pressure). The dynamic component Eadyn is the ratio of PPV and SVV during a
      mechanical ventilator cycle, providing a functional assessment of ventriculo-arterial
      coupling.

      Combined use of arterial pressure tracing (or its non-invasive surrogate) and (non-) invasive
      stroke volume actually may provide an interesting framework for haemodynamic monitoring and
      subsequent optimization in many surgical, postoperative or ICU patients. This study aims to
      copy as good as possible the handling and the way of management as in a clinical setting.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Dynamic Arterial Elastance (Eadyn)</measure>
    <time_frame>baseline and from 30-90 minutes after increase with 20% of vasoactive medication and haemodynamic stabilisation</time_frame>
    <description>display on the hemodynamic monitor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eadyn estimation on haemodynamic monitor</measure>
    <time_frame>from 30 to 90 minutes after increase with 20% of vasoactive medication</time_frame>
    <description>display on the hemodynamic monitor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sepsis</condition>
  <condition>Cardiac Failure Acute</condition>
  <arm_group>
    <arm_group_label>dobutamine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cardiac failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>norepinephrine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sepsis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>dobutamine</intervention_name>
    <description>evaluation of effects of dobutamine on dynamic arterial elastance in cardiac failure</description>
    <arm_group_label>dobutamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>norepinephrine</intervention_name>
    <description>evaluation of effects of norepinephrine on dynamic arterial elastance in sepsis</description>
    <arm_group_label>norepinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - ICU patients, treated/supported with noradrenalin or dobutamine.

        Exclusion Criteria:

          -  Septic shock

          -  Aortic valve regurgitation and defect of septum

          -  Severe aortic sclerosis, aortic prosthesis

          -  Severe hypertension (MAP &gt; 130 mmHg)

          -  Cardiac arrhythmia

          -  Tachycardia with a heart rate higher than 150 bpm

          -  Age below 18 or above 75 y

          -  Patient height below 120 cm (48&quot;) or above 230 cm (90&quot;)

          -  Patient weight less than 30 kg (67 lbs.) or greater than 155 kg (341 lbs.)

          -  Intra-aortic balloon pump
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Poelaert, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Vervoort, IR</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veerle Van Mossevelde, Datanurse</last_name>
    <phone>+32 2 476 31 34</phone>
    <email>veerle.vanmossevelde@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annelies De Cock, Datanurse</last_name>
    <phone>+32 2 474 99 06</phone>
    <email>annelies.decock@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>universitair Ziekenhuis Brussel</name>
      <address>
        <city>Jette</city>
        <state>Vlaams Brabant</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veerle Van Mossevelde</last_name>
      <phone>+3224763134</phone>
      <email>veerle.vanmossevelde@uzbrussel.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Veerle Van Mossevelde</investigator_full_name>
    <investigator_title>Datanurse</investigator_title>
  </responsible_party>
  <keyword>vasoactive medication</keyword>
  <keyword>dynamic arterial elastance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dobutamine</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

